SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
SAB Biotherapeutics will present encore Phase 1 data for SAB-142, its lead fully human anti-thymocyte immunoglobulin candidate for Stage 3 type 1 diabetes, at the inaugural Breakthrough T1D Clinical & Research Congress on October 9-11, 2026 in Philadelphia. Presentations include two oral sessions covering sustained autoimmune balance with induction/maintenance dosing and C-peptide signals in adults more than 100 days post diagnosis, plus three ePosters on PK, redosing safety, and binding specificity.
Key figures
- Drug Name
- SAB-142
- Phase Of Trial
- Phase 1 (encore data); registrational Phase 2b SAFEGUARD ongoing
- Conference
- Breakthrough T1D Clinical & Research Congress (CRC 2026), Oct 9-11, 2026, Philadelphia
- Trial names
- ["SAFEGUARD","PRISE-hATG"]
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.